Azzet reports on three stocks with price moving updates today.
Ramelius Resources soars on buyback and plans to lift dividend ~
Shares in Ramelius Resources (ASX: RMS) were trading 6.7% higher by 1:30 pm AEDT (2:30 am GMT) after the gold miner announced up to A$250 million in share buybacks and increased its minimum dividend to 2 cents per share per year, as part of its FY26–FY27 capital allocation strategy.
Management announced an on-market share buy-back of up to 73.96 million shares from a total of 1.92 billion outstanding, set to commence on 24 December 2025 and conclude by June 2027.
As well as signalling management's confidence in the company's future, a share buyback tends to enhance shareholder returns primarily by reducing the number of outstanding shares, which increases each remaining share's proportional ownership of the company's earnings and assets.
The initiatives aim to enhance capital management and shareholder returns, allowing flexible repurchases at market prices - without needing security holder approval - while continuing to reinvest in the business and uphold a robust balance sheet.
Commenting on today’s update, Ramelius managing director Mark Zeptner told the market that the company’s capital allocation strategy reflects the company’s confidence in sustained free cash flow and a fully funded growth pipeline.
“We remain fully funded, our production profile is growing and we anticipate further increases in our free cash flow returns,” Zeptner said.
Meantime, Ramelius is pursuing fully funded, organically focused growth and is committed to a targeted exploration program centred on discovery and extensions.
The Never Never underground mine at Dalgaranga will continue to be developed during FY26 and FY27 with steady state production of ~1Mtpa scheduled to be achieved in early FY28.
In H2 FY26 and through FY27, Ramelius will be investing in the Mt Magnet hub by upgrading the processing plant, with the throughput increasing to 4.3Mtpa (currently 1.8-2Mtpa) by the September 2027 quarter.
The Eridanus Stage 3 cutback at Mt Magnet is scheduled to commence in the December 2026 Quarter.
The results from exploration activities in the December 2025 Quarter are targeted for release in January 2026.
In FY28, the Ramelius board plans to reset and grow the payout ratio (currently set at a maximum level of 30% of free cash flow) with the new payout ratio factoring in both dividends and/or share buybacks.
Investors should monitor the buy-back's progress and potential impacts on share price and earnings.
Today’s update follows last week’s successful negotiation and execution of a Native Title mining agreement with the Kakarra Part B Native Title holders for the Rebecca-Roe project.
The agreement will facilitate initial development and ongoing operations of the project, delivering what Ramelius said would be economic and social benefits to the Kakarra Part B Native Title holders.
During three years of share price growth, Ramelius has achieved compound earnings per share growth of 156% per year.
This EPS growth is higher than the 64% average annual increase in the share price.
Ramelius Resources has a market cap of $6.9 billion; the share price is up 54% in one year and up 74% year to date.
While the stock’s 200-day moving average is trending upwards and highlights long-term investor interest in the stock, the 20-day moving average is falling as upward momentum wanes.
Consensus is moderate Buy.
Trigg Minerals lifts after secures drilling permit
Shares in Trigg Minerals (ASX: TMG) were trading around 2.5% higher at noon after the junior explorer received tentative approval from Utah’s Division of Oil, Gas and Mining to commence its maiden drilling program at its flagship Antimony Canyon Project (ACP).
The ACP Project - boasts historically rich mines like the Emma and Mammoth - is a significant, undeveloped, high-grade antimony deposit being actively explored and expanded by Trigg Minerals, which aims to become a major domestic U.S. source for this critical metal.
The permit covers 24 drill pads on Trigg’s wholly owned patented claims, targeting the high-grade “Salt n Pepper” tuff unit, where recent sampling returned antimony grades up to 33.2% Sb (antimony).
With site works complete, bonding underway, and Energold Drilling appointed to deliver a 1,650-metre heli-portable diamond program, drilling is expected to commence before the end of December.
Trigg has also added more than 380 new claims to secure district-scale tenure as it moves toward potential pilot-scale studies in 2026.
Commenting on today’s update, managing director Andre Booyzen told the market that securing the drilling permit for Antimony Canyon marks a significant milestone that shifts Trigg from an explorer to an active developer in the U.S. critical minerals sector.
“Our strategy to initially focus on the Patented Claims is paying dividends, allowing us to leverage private land tenure to secure permits efficiently, avoiding potential federal delays,” said Booyzen.
“This is an exciting milestone for us, and this first phase of drilling will help inform our assessment of potential pilot-scale mining activities in 2026.”
The Phase 1 program includes at least 24 diamond drill holes totalling around 5,400.
The program aims to assess the continuity and grade of stibnite mineralisation within the brittle volcanic tuff units that host the district's high-grade mineralisation.
With demand for domestic sources of antimony in the U.S. going through the roof, and prices surging to all-time highs of US$51,500 per tonne in 2025, Trigg has timed the development of the Antimony Canyon project perfectly.
Trigg Minerals has a market cap of $139 million; the share price is up 144% in one year and up 189% year to date.
The stock appears to be in a long-term uptrend.
Its 200-day moving average is upward sloping and shows that there has been investor demand for the stock over the long term.
Consensus does not cover this stock.
4DMedical soars after disclosing another US coup
Shares in 4DMedical (ASX: 4DX) were trading 8.5% higher this afternoon after the healthcare mid-cap stock confirmed that the University of Miami has commenced clinical use of its CT:VQ respiratory imaging technology, becoming the second U.S. academic medical centre after Stanford to adopt the system.
The launch includes a three-month introductory pricing period before full commercial terms take effect, while the technology provides high-resolution, contrast-free lung imaging to support screening, triage, patient management, and therapy planning.
In addition, 4DMedical has signed a two-year agreement with Lahey Hospital & Medical Center for its IQ-UIP software, providing quantitative CT analysis for idiopathic pulmonary fibrosis and related interstitial lung diseases.
Commenting on today’s update, 4DMedical MD/CEO and Founder Andreas Fouras told the market that the immediate transition from strong RSNA engagement to commercial operations demonstrates the significant momentum it's seeing from clinicians seeking a contrast-free, high-resolution alternative to nuclear medicine VQ scans.
“4DMedical is moving with incredible speed. I am excited by the momentum and look forward to keeping you updated as we advance our strategy of winning key U.S. AMCs as reference sites for CT:VQ,” he said.
Today’s update follows a major share price uptick since July – up 680% - after a spate of good news.
In July, the company secured a 3-year contract renewal with the University of Michigan and recently announced that Phillips would add CT:VQ™ to its North American product catalogue, backed by a minimum $15 million contractual order commitment over 2 years.
Then, in September, the company cleared a major hurdle when it received FDA clearance for CT:VQ - a software-as-a-service (SaaS) product that enables doctors to scan for pulmonary embolisms (blood clots) using a standard CT scan, without the need for contrast dye or radioactive tracers.
The FDA clearance opens up an addressable market of US$1.1 billion in the U.S. alone, and it solves a logistical nightmare for hospitals by removing the need for nuclear medicine teams, meaning 4D Medical isn't just selling software; it's selling efficiency.
4DMedical has a market cap of $1.1 billion; the share price is up 344% in one year and up 50% in the last month.
The stock appears to be in a long-term uptrend.
Its 200-day moving average is upward sloping and shows that there has been investor demand for the stock over the long term.
Consensus does not cover this stock.
This article does not constitute financial or product advice. You should consider independent advice before making financial decisions.
